1287220-07-8

Upstream product

• 185677-00-3 2,4-dichloro-6-(2,2,2-trifluoroethoxy)-1,3,5-triazine 
• 619-45-4 4-methoxycarbonyl aniline 

Downstream Products

• 1287220-36-3 methyl 4-(4-(4-hydroxybenzylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoate 
• 1287220-21-6 methyl 4-(4-(2,2-dimethyl-4-oxo-3,9,14-trioxa-5-azaheptadecan-17-ylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoate 
• 1287220-12-5 methyl 4-(4-(8-(tert-butoxycarbonylamino)octylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoate 
• 1373164-27-2 4-(4-(8-(tert-butoxycarbonylamino)octylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoic acid 
• 1360828-44-9 methyl 4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoate 
• 1360828-42-7 tert-butyl 2-(N-(4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoyl)sulfamoyl)ethylcarbamate 
• 1360826-35-2 C₂₇H₂₇ClF₃N₇O₆S 
• 1360826-34-1 4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)-N-(1-(hydroxymethyl)cyclopropylsulfonyl)benzamide 
• 1360826-19-2 C₂₉H₃₁ClF₃N₇O₄S 
• 1360826-09-0 C₂₄H₂₂ClF₃N₆O₄S 
• 1360828-41-6 4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)-N-(1-formylcyclopropylsulfonyl)benzamide 
• 1360828-20-1 tert-butyl 4-(4-(4-(1-((dimethylamino)methyl)cyclopropylsulfonylcarbamoyl)phenylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl)piperazine-1-carboxylate 
• 1360828-76-7 tert-butyl 4-(4-(4-(1-formylcyclopropylsulfonylcarbamoyl)phenylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl)piperazine-1-carboxylate 
• 1360828-75-6 4-(4-(4-(tert-butoxycarbonyl)piperazin-1-yl)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoic acid 

Relevant academic research and scientific papers

COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula (I), including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infe

COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV